The Hoosier Oncology Group (HOG) treated 13 patients with bronchogenic carcinoma and an innovative schedule of cisplatin and VP-16. Unexpected toxicity was noted, and five deaths secondary to granulocytopenia and septic shock and three episodes of renal failure. Despite early closure of this study, we conclude that this schedule of cisplatin and VP-16 results in greater toxicity than comparable dosages in a more routine schedule.
|Original language||English (US)|
|Number of pages||2|
|Journal||American Journal of Clinical Oncology: Cancer Clinical Trials|
|State||Published - Jan 1 1988|
ASJC Scopus subject areas
- Cancer Research